e-learning
resources
Madrid 2019
Sunday, 29.09.2019
Comorbidities of idiopathic pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The health status in idiopathic pleuroparenchymal fibroelastosis
Y. Mori (Seto, Japan), Y. Yamano (Seto, Japan), T. Yokoyama (Seto, Japan), T. Matsuda (Seto, Japan), K. Kataoka (Seto, Japan), T. Kimura (Seto, Japan), Y. Kondoh (Seto, Japan)
Source:
International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Session:
Comorbidities of idiopathic pulmonary fibrosis
Session type:
Thematic Poster
Number:
1315
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Mori (Seto, Japan), Y. Yamano (Seto, Japan), T. Yokoyama (Seto, Japan), T. Matsuda (Seto, Japan), K. Kataoka (Seto, Japan), T. Kimura (Seto, Japan), Y. Kondoh (Seto, Japan). The health status in idiopathic pleuroparenchymal fibroelastosis. 1315
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Clinical courses of asymptomatic patients with mild idiopathic pleuroparenchymal fibroelastosis
Source: International Congress 2018 – New insights in rare diffuse parenchymal lung diseases (DPLDs) in adults and children
Year: 2018
Treatment with nintedanib in patients with pleuroparenchymal fibroelastosis
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Predicting factors for mortality in patients with pleuroparenchymal fibroelastosis
Source: International Congress 2017 – Rare diseases
Year: 2017
Clinical and pathological features of idiopathic and secondary pleuroparenchymal fibroelastosis in patients undergoing lung transplantation
Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases
Year: 2019
Pleuroparenchymal fibroelastosis as a manifestation of chronic lung rejection?
Source: Eur Respir J 2013; 41: 243-245
Year: 2013
Prognostic and clinical value of cluster analysis of idiopathic pleuroparenchymal fibroelastosis phenotypes
Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia
Year: 2019
Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact
Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
Architectural remodelling in idiopathic interstitial pneumonias: fibrosis or fibroelastosis?
Source: Eur Respir J 2004; 24: Suppl. 48, 557s
Year: 2004
Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes
Source: Eur Respir J 2012; 40: 377-385
Year: 2012
Treatment with antifibrotic agents in idiopathic pleuroparenchymal fibroelastosis with usual interstitial pneumonia
Source: ERJ Open Res, 7 (1) 00196-2020; 10.1183/23120541.00196-2020
Year: 2021
Pleuroparenchymal fibroelastosis from a consecutive database: a rare disease entity?
Source: Eur Respir J 2015; 45: 1183-1186
Year: 2015
Bullous emphysema in adolescent: is congenital malformation or outcome of bronchopulmonary dysplasia?
Source: International Congress 2019 – Paediatric respiratory diseases
Year: 2019
Never-smoking history as a poor prognostic factor in surgically proven idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Air-leak syndrome caused by pleuroparenchymal fibroelastosis after bone marrow transplantation
Source: International Congress 2015 – Interstitial lung diseases I
Year: 2015
Clinical features of patients with idiopathic pulmonary upper lobe-dominant fibrosis
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Idiopathic hyperventilation impairs health status
Source: Eur Respir J 2003; 22: Suppl. 45, 442s
Year: 2003
Pleuroparenchymal fibroelastosis - clinical analysis of 22 cases
Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases
Year: 2019
A rare case of idiopathic pulmonary fibrosis in children
Source: Eur Respir J 2007; 30: Suppl. 51, 390s
Year: 2007
The thoracic cage becomes flattened in the progression of pleuroparenchymal fibroelastosis
Source: Eur Respir Rev 2014; 23:263-266
Year: 2014
Idiopathic pulmonary fibrosis: does smoking status influence outcome?
Source: Eur Respir J 2006; 28: Suppl. 50, 830s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept